<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04524494</url>
  </required_header>
  <id_info>
    <org_study_id>EK1744; ks20Vuille</org_study_id>
    <nct_id>NCT04524494</nct_id>
  </id_info>
  <brief_title>Human Intestinal Amino Acid Absorption and the Role of a Local RAS</brief_title>
  <official_title>Human Intestinal Amino Acid Absorption and the Role of a Local (Renin)-Angiotensin System (RAS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Children's Hospital Basel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Children's Hospital Basel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to find out what role a local intestinal RAS (renin angiotensin system) plays&#xD;
      in the context of amino acid absorption in the human intestinal tract and how this RAS and&#xD;
      thus the amino acid absorption is influenced by the RAS-active drugs (angiotensin II AT1&#xD;
      receptor blockers (sartans) or ACE inhibitors).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 27, 2010</start_date>
  <completion_date type="Actual">May 31, 2011</completion_date>
  <primary_completion_date type="Actual">May 31, 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>messenger ribonucleic acid (mRNA) quantification in intestinal tissue biopsy</measure>
    <time_frame>single time-point at baseline</time_frame>
    <description>mRNA quantification in intestinal tissue biopsy: mRNA content coding for regulatory RAS protein is measured relative to the mRNA content, which codes for the structural protein villin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>amino acid concentration in blood sample</measure>
    <time_frame>single time-point at baseline</time_frame>
    <description>amino acid concentration in blood sample by High Performance Liquid Chromatography (HPLC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>amino acid concentration in urine sample</measure>
    <time_frame>single time-point at baseline</time_frame>
    <description>amino acid concentration in urine sample by HPLC (High Performance Liquid Chromatography)</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">50</enrollment>
  <condition>Renin-Angiotensin Aldosterone System (RAS)</condition>
  <arm_group>
    <arm_group_label>RAS- active medication</arm_group_label>
    <description>Patients taking RAS- active medication (ACE- Inhibitor, Angiotensin II AT1 Antagonist (Sartan)) on a daily Basis for at least 6 months for medical reasons</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no RAS- active medication</arm_group_label>
    <description>Patients not taking RAS- active medication</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>biopsy of intestinal tissue</intervention_name>
    <description>4 intestinal tissue biopsies taken from descending Duodenum, 2 intestinal tissue biopsies taken from Ileum, 2 intestinal tissue biopsies taken from ascending colon (additional to routine biopsies taken for gastrointestinal diagnostic)</description>
    <arm_group_label>RAS- active medication</arm_group_label>
    <arm_group_label>no RAS- active medication</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood draw</intervention_name>
    <description>40 ml blood draw (in Heparin blood tubes) (additional to routine blood draw taken for gastrointestinal diagnostic)</description>
    <arm_group_label>RAS- active medication</arm_group_label>
    <arm_group_label>no RAS- active medication</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>urine collection</intervention_name>
    <description>Midstream Urine collection</description>
    <arm_group_label>RAS- active medication</arm_group_label>
    <arm_group_label>no RAS- active medication</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      intestinal tissue samples blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undertaking a gastroscopy and / or colonoscopy for a medical indication&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body Mass Index (BMI): 18-35 kg/m2&#xD;
&#xD;
          -  cohort 1: therapy with an angiotensin II AT1 antagonist or ACE Inhibitor&#xD;
&#xD;
          -  cohort 2: no therapy with an angiotensin II AT1 antagonist or ACE Inhibitor&#xD;
&#xD;
          -  Carrying out a diagnostic gastroscopy, colonoscopy or a combined gastroscopy /&#xD;
             colonoscopy&#xD;
&#xD;
          -  Existence of written consent after detailed information about the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe pathological changes in the gastrointestinal tract (e.g. sprue, stomach ulcers,&#xD;
             malignancies); (reflux esophagitis and gastritis are not Exclusion criteria)&#xD;
&#xD;
          -  History of gastrointestinal tract surgery (except for appendectomy and inguinal hernia&#xD;
             surgery)&#xD;
&#xD;
          -  History of malignancy&#xD;
&#xD;
          -  Severe acute and chronic organ diseases requiring treatment (e.g. kidney replacement&#xD;
             therapy)&#xD;
&#xD;
          -  Patients with an increased risk of bleeding (e.g. oral anticoagulation, coagulation&#xD;
             disorders)&#xD;
&#xD;
          -  Drug or alcohol abuse&#xD;
&#xD;
          -  Mental impairment limiting the ability to meet all study requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raphael N Vuille-dit-Bille, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitäts-Kinderspital beider Basel (UKBB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitäts-Kinderspital beider Basel (UKBB)</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitätsSpital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 19, 2020</study_first_submitted>
  <study_first_submitted_qc>August 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2020</study_first_posted>
  <last_update_submitted>August 19, 2020</last_update_submitted>
  <last_update_submitted_qc>August 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renin Angiotensin System</keyword>
  <keyword>Angiotensin Converting Enzyme 2 (ACE2)</keyword>
  <keyword>Angiotensin II AT1 Receptor Blocker</keyword>
  <keyword>ACE inhibitors</keyword>
  <keyword>intestinal amino acid absorption</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

